HTG Molecular Diagnostics (HTGM) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Survey Shows Low Awareness and Purchase Intent on HTG Molecular Diagnostics (HTGM); Leerink Partners Cuts Price Target to $10
November 13, 2015 10:12 AM ESTLeerink Partners reiterates an Outperform rating on HTG Molecular Diagnostics (NASDAQ: HTGM), and cut the price target to $10.00 (from $18.00), following the company's 3Q15 earnings report. HTGM reported Q3 revenue of $1M, in line with the Street expectation. However, Survey work suggests awareness of its... More



